Volitionrx Limited

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

VolitionRx reports 240% revenue growth, eyes expansion in veterinary diagnostics

VolitionRx reported strong revenue growth in 2022 but faced a net loss due to higher costs, emphasizing the need for cost management.
The company's focus on commercializing its Nu.Q platform and expanding into veterinary diagnostics presents growth opportunities.
While challenges like increased expenditures and competition exist, VolitionRx's strategic partnerships and product pipeline position it for future success.
Exploring new applications of NETosis technology in animal health and upcoming investor events highlight potential growth avenues for VolitionRx.

VolitionRx reports robust Q1 results, eyes growth in cancer testing

VolitionRx Limited's Q1 2023 performance reflects strong financials, strategic partnerships, and promising revenue from innovative cancer testing products.
The company's strengths include financial stability, strategic collaborations, and growth potential in the veterinary and cancer testing markets.
Challenges in managing expenses, sustaining revenue growth, and strategic focus require careful navigation for continued success.
Opportunities abound in leveraging partnerships, exploring new markets, and proactive initiatives for future growth and market expansion.

VolitionRx reports robust Q2 earnings, poised for growth in cancer diagnostics

VolitionRx Limited delivered a strong performance in Q2 2023, marked by significant revenue growth and a solid financial position, underpinned by cash reserves and milestone payments.
The company's focus on advancing Nu.Q technology, expanding partnerships, and making progress in cancer research bodes well for future growth and innovation.
While facing challenges in scaling sales efforts and managing R&D expenses, VolitionRx has opportunities to drive revenue growth through strategic partnerships and market expansion.

VolitionRx reports robust revenue growth and global expansion opportunities

VolitionRx Limited's Q3 2023 performance showcased strong revenue growth and global expansion in Nu.Q Vet Cancer Test sales.
While facing challenges in regulatory timelines and funding, the company's strategic strengths lie in its innovative products and prudent financial approach.
Opportunities in new product launches, market education, and global expansion position VolitionRx for continued growth and breakthroughs in cancer detection.

VolitionRx reports stellar revenue growth, eyes global expansion with strategic partnerships

VolitionRx Limited's Q4 2023 earnings call highlighted robust revenue growth, strong cash position, and strategic partnerships driving expansion. While facing challenges in financing and operational efficiency, the company's focus on innovative technologies and global market penetration positions it well for future growth and partnerships.

Volitionrx reports revenue growth and eyes cash flow positivity by 2025

Volitionrx Limited (VNRX) is on track for growth with strong revenue performance, successful product launches, and a focus on achieving cash flow positivity. The company faces challenges in expense control and funding strategies but has opportunities in upcoming data releases and licensing deals.

Volitionrx reports robust Q3 revenue growth and strategic advancements

Volitionrx Limited demonstrated strong performance in revenue growth, innovation, and financial progress.
Key strengths include successful product sales, research advancements, and strategic financial planning.
Challenges in market dynamics and cost management require strategic focus and operational efficiency improvements.
Opportunities for growth exist in market expansion, cost optimization, new partnerships, and research publications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Cutera

Omega Therapeutics

Revolution Medicines

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Are Preparing To Pump This Quarter - Omega Therapeutics (NASDAQ:OMGA), Cutera (NASDAQ:CUTR)

VolitionRx (NYSE-A:VNRX) Limited has announced that it is participating in a webinar hosted by Edison Group, to expound new cancer data to be presented on October 21 at ESMO 2023, the annual congress of the European Society for Medical Oncology.  The multi-national epigenetics company said the webinar will take place on Thursday, October 26 at 10:30 AM EDT and will include updates from Volition's chief scientific officer Dr Jake Micallef, its chief commercial officer Gael Forterre, as well as Dr Andrew Retter, a leading UK-based haematologist and medical consultant at Volition.

VolitionRx to unveil new cancer detection method insights at upcoming webinar

HENDERSON, Nev. , Oct. 2, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expound new cancer data to be presented on October 21 st at ESMO 2023, the annual congress of the European Society for Medical Oncology.

Volition to Reveal New Cancer Detection Method Insights at Upcoming Webinar

VolitionRx (NYSE-A:VNRX) said it is hosting a roundtable discussion in Athens this weekend which will bring together world-renowned experts in sepsis, a life-threatening condition that occurs in response to an infection.    The company said the roundtable, chaired by Professor of Medicine at University Paris Saclay-UVSQ Djillali Annane, will cover the challenges of sepsis, the link between Neutrophil Extracellular Traps (NETs) and sepsis and how Volition's Nu.Q NETs technology could potentially be used effectively in clinical practice.

VolitionRx to host sepsis management roundtable

HENDERSON, Nev. , Sept. 13, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a Key Opinion Leader ("KOL") roundtable discussion in Athens this weekend, bringing together world-renowned experts in sepsis.

Volition Hosts Key Opinion Leader Roundtable on Sepsis Management

VolitionRx Limited (NYSE:VNRX ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - Founder, CEO, President and Director Terig Hughes - CFO & Treasurer Tom Butera - CEO, Volition Veterinary Diagnostics Development LLC Conference Call Participants Bruce Jackson - Benchmark Company Steven Ralston - Zacks Operator Good morning, ladies and gentlemen. Thank you for standing by.

VolitionRx Limited (VNRX) Q2 2023 Earnings Call Transcript

Conference call to discuss financial and operational results scheduled for Tuesday, August 15, at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

VolitionRx Limited Announces Second Quarter 2023 Financial Results and Business Update

Conference call to take place on Tuesday, August 15 at 8:30 a.m. Eastern Time HENDERSON, Nev , Aug. 9, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, August 15 at 8.30 a.m.

VolitionRx Limited Schedules Second Quarter 2023 Earnings Conference Call and Business Update

HENDERSON, Nev. , June 23, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that the underwriters of its previously announced underwritten public offering of its common stock have exercised their option to purchase an additional 1,950,000 shares to cover over allotments, bringing the total gross proceeds to Volition from the offering to approximately $19.0 million, before deducting underwriting commissions and other offering expenses payable by Volition.

VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriters

HENDERSON, Nev. , June 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of its common stock generating gross proceeds to Volition from the offering of approximately $16.5 million, before deducting underwriting commissions and other offering expenses payable by Volition.

VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock

VolitionRx (NYSE-A:VNRX) Limited announced the pricing of an underwritten public offering with expected gross proceeds of $16.5 million. The epigenetics company plans to offer 13 million shares at $1.27 per share.

VolitionRx Limited prices major public offering to fund research and product development

HENDERSON, Nev. , June 1, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 13,000,000 shares of its common stock at a public offering price of $1.27 per share.

VolitionRx Limited Announces Pricing of $16.5 Million Underwritten Public Offering of Common Stock

HENDERSON, Nev. , May 31, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of shares of its common stock.

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

VolitionRx Limited (NYSE:VNRX ) Q1 2023 Earnings Call May 11, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations. Cameron Reynolds - President and Group Chief Executive Officer Tom Butera - Chief Executive Officer of our Volition Veterinary subsidiary Terig Hughes - Group Chief Financial Officer Conference Call Participants Bruce Jackson - The Benchmark Company Steven Ralston - Zacks Ross Osborn - Cantor Fitzgerald Operator Good morning, ladies and gentlemen.

VolitionRx Limited (VNRX) Q1 2023 Earnings Call Transcript

VolitionRx (NYSE-A:VNRX) Limited said it had cash and cash equivalents of around $10 million as of March 31, 2023, as it announced financial results and a business update for the first quarter. The company said it received approximately $8 million through an underwritten public offering of its common stock in February, adding that it expects to receive a further $13 million in milestone payments from Heska Corporation and additional funding from three Belgian agencies over the coming months.

VolitionRx reports cash and cash equivalents of $10M at 1Q-end

HENDERSON, Nev. , May 11, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces new research - published in PLOS ONE - which reveals that plasma nucleosome concentrations can be a useful tool for treatment monitoring and disease progression in dogs with hematopoietic cancers.

Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment Monitoring

Conference call to discuss financial and operational results scheduled for  Thursday, May 11, at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update

Conference call to take place on Thursday May 11 at 08:30 a.m. Eastern Time Capital Markets Day - Thursday May 11 at 2:00 p.m.

VolitionRx Limited Schedules First Quarter 2023 Earnings Conference Call and Business Update

HENDERSON, Nev. , April 26, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company is hosting a Capital Markets Day in a hybrid format (in-person and live-webcast) on Thursday, May 11, 2023, at 2 p.m.

VolitionRx Limited to Host Capital Markets Day at the NYSE on Thursday May 11.

VolitionRx Limited (NYSE-A:VNRX) has reported a sharp rise in annual revenue as it ‘shifts gears' towards its goal of becoming a commercial company with products.   The company, which is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals, recorded revenue of approximately $300,000 for the year to December 31, 2022, up 240% over the prior year.

VolitionRx posts 240% rise in 2022 revenue; outlines upcoming milestones

Conference call to discuss financial and operational results scheduled for Thursday, March 16, at 8:30 a.m. U.S. Eastern Time Executed global licensing and supply agreement with Heska Corporation ("Heska") to distribute Nu.Q® Vet Cancer Test at the Point of Care with a $10 million upfront payment and up to $18 million based upon the achievement of near/mid-term milestones.

VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update

Conference call to take place on Thursday March 16 at 08:30 a.m. Eastern Time HENDERSON, Nev.

VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update

HENDERSON, Nevada , Feb. 22, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of 4,945,000 shares of its common stock, including the exercise in full of the underwriter's overallotment option, at a public offering price of $1.75 per share. The gross proceeds to Volition from the offering, before deducting underwriting commissions and other offering expenses payable by Volition, were approximately $8.7 million.

VolitionRx Limited Announces Closing of $8.7 Million Underwritten Public Offering of Common Stock

VolitionRx (NYSE-A:VNRX) Limited announced that it has priced its underwritten public offering of 4.3 million company common shares at $1.75 per share, with expected gross proceeds to Volition of $7.525 million. The multi-national epigenetics company said it intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.

VolitionRx reveals pricing of its $7.5M public equity offering

VolitionRX (NYSEMKT: VNRX ) stock is taking a beating on Friday after the company revealed a proposed public offering for its shares. The big news here is VolitionRX planning a public offering of it VNRX stock.

News for Volitionrx Limited Stock (VNRX)